A Prospective, Single-arm, Multicenter, Uncontrolled, Open-label Phase II Trial of Refametinib (BAY86-9766) in Combination With Sorafenib as First Line Treatment in Patients With RAS Mutant Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase II
Latest Information Update: 04 Jun 2019
Price : $35 *
At a glance
- Drugs Refametinib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Sponsors Bayer
- 27 Jun 2018 Results published in the Clinical Cancer Research
- 12 May 2017 Status changed from active, no longer recruiting to completed.
- 20 Apr 2017 This trial has been completed in Hungary (end date: 8 Feb 2017).